Cepheid Delays Launch of Omni Point-of-Care MDx System | GenomeWeb

NEW YORK (GenomeWeb) – Cepheid said yesterday that it will delay the international market launch of its point-of-care platform, the Omni, by one year to the third quarter of 2017.

The firm's stock fell sharply on the news, down more than 19 percent on Nasdaq at mid-day trading following the announcement.

Cepheid first unveiled the Omni in July 2015, when it also announced plans to develop a line of more rapid tests, called Xpert Xpress.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.